
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
The diversity & agility of API supply chains is key to ensuring that medicines can be manufactured & delivered to patients; this Ebook explores the path to a secure supply chain.





